Multiple vaccination including serogroup C meningococcus
AssigneeNovartis Vaccines and Diagnostics, Inc.
InventorAstrid Borkowski
Life of this patent
Estimating the term…
Abstract
Various improvements to vaccines that include a serogroup C meningococcal conjugate antigen, including: (a) co-administration with acellular B. pertussis antigen; (b) co-administration with an inactivated poliovirus antigen; (c) supply in a kit together with a separate pneumococcal conjugate component, which may be in a liquid form; and (d) use in combination with a pneumococcal conjugate antigen but without an aluminum phosphate adjuvant. A kit may have: (a) a first immunogenic component that comprises an aqueous formulation of a conjugated capsular saccharide from Streptococcus pneumoniae; (b) a second immunogenic component that comprises a conjugated capsular saccharide from Neisseria meningitidis serogroup C.
Claims40
A kit, comprising a first immunogenic component and a second immunogenic component, wherein:
- (a) the first immunogenic component comprises an aqueous formulation of a diphtheria toxoid, a tetanus toxoid and acellular B. pertussis antigen;
- and (b) the second immunogenic component comprises a conjugated capsular saccharide from a OAc+ strain of N. meningitidis serogroup C and a conjugated H. influenzae type b antigen, in lyophilised form.
A kit comprising a first immunogenic component, a second immunogenic component, and a third immunogenic component, wherein:
- (a) the first immunogenic component comprises an aqueous formulation of a diphtheria toxoid, a tetanus toxoid and acellular B. pertussis antigen;
- and (b) the second immunogenic component comprises a conjugated capsular saccharide from a OAc+ strain of N. meningitidis serogroup C, in lyophilised form and (c) the third immunogenic component comprises saccharide antigens for at least S. pneumoniae serotypes 6B, 14, 19F and 23F.
Dependencies are inferred from the claim text.